83863-73-4

Basic information

• Product Name: ethyl 3,4,4-trimethoxypiperidine-1-carboxylate
• Synonyms: ethyl 3,4,4-trimethoxypiperidine-1-carboxylate;3,4,4-Trimethoxy-1-piperidinecarboxylic acid ethyl ester
• CAS NO: 83863-73-4
• Molecular Formula: C11H21NO5
• Molecular Weight: 247.28814
• EINECS: 281-139-6
• Mol File: 83863-73-4.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 301.7°C at 760 mmHg
• Flash Point: 136.2°C
• Appearance: /
• Density: 1.11g/cm³
• Vapor Pressure: 0.00104mmHg at 25°C
• Refractive Index: 1.471
• Storage Temp.: 2-8°C
• PKA: -4.31±0.60(Predicted)
• CAS DataBase Reference: ethyl 3,4,4-trimethoxypiperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 3,4,4-trimethoxypiperidine-1-carboxylate(83863-73-4)
• EPA Substance Registry System: ethyl 3,4,4-trimethoxypiperidine-1-carboxylate(83863-73-4)

Safety Data

• Hazardous Substances Data: 83863-73-4(Hazardous Substances Data)

Usage

Description

Ethyl 3,4,4-trimethoxypiperidine-1-carboxylate, also known as Ethyl (?)-vesamicol, is a chemical compound with the molecular formula C12H21NO5. It is a piperidine derivative featuring three methoxy groups attached to the piperidine ring. This versatile chemical compound is commonly used in the synthesis of pharmaceuticals and agrochemicals, and is being researched for its potential applications in the medical field, particularly in the development of new drugs. It has also been studied for its potential use as an insecticide.

Uses

Used in Pharmaceutical Industry:
Ethyl 3,4,4-trimethoxypiperidine-1-carboxylate is used as an intermediate in the synthesis of pharmaceuticals for its potential biological activity. It plays a crucial role in the development of new drugs, contributing to the advancement of medical treatments.
Used in Agrochemical Industry:
Ethyl 3,4,4-trimethoxypiperidine-1-carboxylate is used as a component in the development of agrochemicals, specifically as a potential insecticide. Its application aims to improve pest control methods in agriculture, enhancing crop protection and yield.

InChI:InChI=1/C11H21NO5/c1-5-17-10(13)12-7-6-11(15-3,16-4)9(8-12)14-2/h9H,5-8H2,1-4H3

Upstream product

• 83898-43-5 ethyl 3-hydroxy-4,4-dimethoxy-1-piperidinecarboxylate 
• 74-88-4 methyl iodide 
• 127364-16-3 3,4,4-trimethoxy-piperidine 
• 541-41-3 chloroformic acid ethyl ester 
• 29976-53-2 N-ethoxycarbonyl-4-piperidone 

Downstream Products

• 83863-72-3 (-)-ethyl 3-methoxy-4-oxo-1-piperidine-carboxylate 
• 907543-85-5 ethyl (3R,4S)-4-(benzylamino)-3-methoxypiperidine-1-carboxylate 
• 907543-86-6 ethyl (3S,4R)-4-(benzylamino)-3-methoxypiperidine-1-carboxylate 
• 882737-71-5 ethyl (3S,4R)-4-amino-3-methoxypiperidine-1-carboxylate 
• 907572-18-3 ethyl (-)-cis-4-amino-3-methoxy-1-piperidinecarboxylate 
• 128225-42-3 cis(+/-) ethyl 4-amino-3-methoxypiperidine-1-carboxylate 

Relevant articles and documents

LUMINALLY-ACTING N-(PIPERIDIN-4-YL)BENZAMIDE DERIVATIVES

Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein m, R1, R2, R3, R4, R5, R6, X1, X2, X3 and X4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with the 5-HT4 receptor.

Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099)

AZD5099 (compound 63) is an antibacterial agent that entered phase 1 clinical trials targeting infections caused by Gram-positive and fastidious Gram-negative bacteria. It was derived from previously reported pyrrolamide antibacterials and a fragment-based approach targeting the ATP binding site of bacterial type II topoisomerases. The program described herein varied a 3-piperidine substituent and incorporated 4-thiazole substituents that form a seven-membered ring intramolecular hydrogen bond with a 5-position carboxylic acid. Improved antibacterial activity and lower in vivo clearances were achieved. The lower clearances were attributed, in part, to reduced recognition by the multidrug resistant transporter Mrp2. Compound 63 showed notable efficacy in a mouse neutropenic Staphylococcus aureus infection model. Resistance frequency versus the drug was low, and reports of clinical resistance due to alteration of the target are few. Hence, 63 could offer a novel treatment for serious issues of resistance to currently used antibacterials.

DIMETHYLBENZOFURAN AND DIMETHYLBENZOPYRAN DERIVATIVES AND THEIR USE AS 5-HT3 ANTAGONISTS

Method of treating 5-HT 3-mediated disorders, which comprises systemic administration of an effective amount of a compound of formula (I) STR1 the pharmaceutically acceptable acid addition salt forms and the stereochemically isomeric forms thereof, wherein R 1 and R 2 represent hydrogen, or R 1 and R 2 taken together form a bivalent radical of formula--CH=CH--CH=CH--(a),--CH=C(Cl)--CH= CH--(b) or--CH=CH--C(Cl)=CH--(c); n represents 2, 3 or 4; R. sup.3 represents hydrogen or methoxy; m represents 1 or 2; R 4 represents hydrogen, amino or C 1-3-alkylcarbonylamino; and R 5 represents hydrogen or halo; novel compounds; compositions; processes for preparing novel compounds and intermediates.